Table 2 Treatment characteristics for patients with limited stage small cell lung cancer (LS-SCLC) treated with chemoradiation, (n = 105)
Treatment | N = 105 (%) |
|---|---|
Induction chemotherapy | 85 (81%) |
Concurrent chemoradiation | 92 (88%) |
Radiation alone | 13 (12%) |
Post-radiation chemotherapy | 53 (50%) |
Any chemotherapy | 102 (97%) |
Chemotherapy type | |
Cisplatin/etoposide | 79 |
Carboplatin/etoposide | 11 |
Carboplatin/taxol | 1 |
Cisplatin/irinotecan | 1 |
Not available | 2 |
Median number of chemotherapy cycles (range) | 3 (2–7) |
PCIa | |
Yes | 63 (60%) |
No | 42 (40%) |
Median RT dose received (range) | 45 (20–66.6) |
Daily | 52 (49%) |
BID | 51 (49%) |
Not available | 2 (2%) |